Evaxion Biotech A/S Adr (EVAX)
NASDAQ:EVAX
Want to see EVAX full AI Analyst Report?
EVAX Stock Chart & Stats
$4.45
-$0.02(-2.40%)
At close: 4:00 PM EST
$4.45
-$0.02(-2.40%)
Day’s Range― - ―
52-Week Range$2.07 - $12.15
Previous CloseN/A
Volume99.85K
Average Volume (3M)33.49K
Market Cap
$33.36M
Enterprise Value$9.54M
Total Cash (Recent Filing)$23.23M
Total Debt (Recent Filing)$7.50M
Price to Earnings (P/E)―
Beta1.93
Next Earnings
Aug 20, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.52
Shares Outstanding8,340,215
10 Day Avg. Volume29,932
30 Day Avg. Volume33,489
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.79
Price to Sales (P/S)4.06
P/FCF Ratio-4.59
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue1.27
Enterprise Value/Gross Profit1.27
Enterprise Value/Ebitda-1.09
Forecast
1Y Price Target
$11.25Price Target Upside152.81% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.03
Revenue Forecast (FY)$5.27M
Bulls Say, Bears Say
Bulls Say
AI Platform AdvantageProprietary AI-Immunology technology reduces time and cost to discover and optimize vaccine targets, giving a competitive edge in sourcing novel candidates and attracting development partners.
Clinical EfficacyFollow-up clinical data for the personalized melanoma vaccine showed strong and durable patient responses with sustained immune activity, supporting the program's potential for late-stage development and partner interest.
Strategic PartnershipsStrategic collaboration with a major pharmaceutical partner that exercised an option on a preclinical infectious disease candidate generated an upfront licensing payment and preserves eligibility for future milestone and royalty payments, validating the platform and providing non-dilutive funding.
Bears Say
Financing RiskReported cash resources may be inadequate relative to projected cash burn, creating a need for additional financing that could dilute shareholders or increase borrowing costs before partner revenues are realized.
Regulatory RiskRegulatory uncertainty in infectious disease programs could complicate approval pathways and limit the commercial outlook for affected vaccine candidates.
Scalability And ExecutionBusiness model reliance on partnering and personalized neoantigen vaccines introduces scaling and manufacturing constraints, and the investment case depends heavily on successful clinical milestones and licensing deals.
Evaxion Biotech News
EVAX FAQ
What was Evaxion Biotech A/S Adr’s price range in the past 12 months?
Evaxion Biotech A/S Adr lowest stock price was $2.07 and its highest was $12.15 in the past 12 months.
What is Evaxion Biotech A/S Adr’s market cap?
Evaxion Biotech A/S Adr’s market cap is $33.36M.
When is Evaxion Biotech A/S Adr’s upcoming earnings report date?
Evaxion Biotech A/S Adr’s upcoming earnings report date is Aug 20, 2026 which is in 81 days.
How were Evaxion Biotech A/S Adr’s earnings last quarter?
Evaxion Biotech A/S Adr released its earnings results on May 07, 2026. The company reported -$0.01 earnings per share for the quarter, the consensus estimate of -$0.01 by $0.
Is Evaxion Biotech A/S Adr overvalued?
According to Wall Street analysts Evaxion Biotech A/S Adr’s price is currently Undervalued.
Does Evaxion Biotech A/S Adr pay dividends?
Evaxion Biotech A/S Adr does not currently pay dividends.
What is Evaxion Biotech A/S Adr’s EPS estimate?
Evaxion Biotech A/S Adr’s EPS estimate is -0.01.
How many shares outstanding does Evaxion Biotech A/S Adr have?
Evaxion Biotech A/S Adr has 8,340,215 shares outstanding.
What happened to Evaxion Biotech A/S Adr’s price movement after its last earnings report?
Evaxion Biotech A/S Adr reported an EPS of -$0.01 in its last earnings report, expectations of -$0.01. Following the earnings report the stock price went down -7.71%.
Which hedge fund is a major shareholder of Evaxion Biotech A/S Adr?
Currently, no hedge funds are holding shares in EVAX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evaxion Biotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$11.25 (152.81% Upside)
$11.25 (152.81% Upside)
Hedge Fund Trend
Decreased
By 10.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.7%
Last 30 Days ▲ 11.6%
Last 30 Days ▲ 11.6%
Technicals
SMA
Negative
20 days / 200 days
Momentum
73.91%
12-Months-Change
Fundamentals
Return on Equity
-77.90%
Trailing 12-Months
Asset Growth
-6.33%
Trailing 12-Months
Company Description
Evaxion Biotech A/S Adr
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
EVAX Company Deck
EVAX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong R&D and platform momentum, highlighted by robust EVX-01 immunogenicity (86% immunogenicity and de novo response rates), supportive clinical signals (75% overall response rate previously reported), platform scalability into GBM (fully personalized designs for 24/24 cases, with 21/24 designs including both neoantigen and ERV components), and novel vaccine concepts (polio work with The Gates Foundation). The company also reinforced disciplined financial management and confirmed cash runway into H2 2027. Key risks discussed include a finite cash runway, a Q1 net loss of USD 3.6M and reduced equity, and the absence of finalized partnerships to extend funding or accelerate certain programs. On balance, the positive clinical and platform developments materially outweigh the financial and partnership uncertainties, though the latter remain important near-term considerations.View all EVAX earnings summariesEVAX Stock 12 Month Forecast
Average Price Target
$11.25
▲(152.81% Upside)
Technical Analysis
Ownership Overview
―
Insiders
<0.01% Mutual Funds
2.33% Other Institutional Investors
97.67% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---